Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855136 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT04855136 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 21 participants.
The verdict
NCT04855136, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be * Arm A will test bb2121 in combination with CC-220 (± low-dose dexamethasone) * Arm B will test bb2121 in combination with BMS-986405 (JSMD194) Combination agents being tested may be administered before, concurrently with and/or following (ie, maintenance) bb2121 infusion. The study will consist of 2 parts: dose finding (Phase 1) and dose expansion (Phase 2). Dose expansion may occur in one or more arms.
Interventions
- DRUG CC-220
- DRUG BMS-986405
- BIOLOGICAL BB2121
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2021-06-01 |
| Est. Completion | 2025-04-25 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855136
The ClinicalTrials.gov registry entry for NCT04855136 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CC-220 is the first listed.
NCT04855136 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855136 about?
NCT04855136 is a clinical study titled "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma". This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be * Arm A will test bb2121 in combination with CC-22...
What is the current status of trial NCT04855136?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2021-06-01. Estimated completion is 2025-04-25.
What interventions are being tested in trial NCT04855136?
The interventions under investigation include: CC-220 (DRUG), BMS-986405 (DRUG), BB2121 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04855136?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.